Oculis Holding AG
Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.
OCS | IC
Overview
Corporate Details
- ISIN(s):
- CH1242303498 (+1 more)
- LEI:
- 5067005370C2KK324336
- Country:
- Switzerland
- Address:
- Bahnhofstrasse 7, 6300 Zug
- Website:
- https://www.oculis.com/
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
Oculis Holding AG is a global, clinical-stage biopharmaceutical company dedicated to developing innovative therapies to save sight and improve eye care. The company focuses on ophthalmology, addressing diseases with high unmet medical needs through a pipeline of novel treatment candidates. Its key assets include OCS-01, a topical eye drop using its proprietary OPTIREACH® technology for Diabetic Macular Edema (DME); Licaminlimab (OCS-02), an anti-TNFα eye drop for Dry Eye Disease (DED); and Privosegtor (OCS-05), a neuroprotective therapy for Acute Optic Neuritis. Oculis aims to transform treatment paradigms by developing potentially first-in-class, non-invasive therapies for major ocular diseases.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-10-06 10:07 |
Regulatory News Service
Oculis hrindir af stað skráningarrannsóknum á Privosegtor við bráðri sjóntaugab…
|
Icelandic | 18.7 KB | ||
| 2025-10-06 10:07 |
Regulatory News Service
Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neurit…
|
English | 16.8 KB | ||
| 2025-09-26 22:05 |
Director's Dealing
Oculis Publishes Notification of Transactions by Person Discharging Managerial …
|
English | 1.0 KB | ||
| 2025-09-22 10:00 |
Regulatory News Service
Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor …
|
English | 11.4 KB | ||
| 2025-09-09 22:05 |
Director's Dealing
Oculis Publishes Notifications of Transactions by Persons Discharging Manageria…
|
English | 952 bytes | ||
| 2025-09-04 19:00 |
Regulatory News Service
Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025
|
English | 6.5 KB | ||
| 2025-09-03 22:05 |
Director's Dealing
Oculis Publishes Notifications of Transactions by Persons Discharging Manageria…
|
English | 950 bytes | ||
| 2025-09-01 10:00 |
Regulatory News Service
Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Op…
|
English | 17.7 KB | ||
| 2025-08-28 10:00 |
Regulatory News Service
Oculis to Participate in Upcoming September Investor Conferences
|
English | 6.1 KB | ||
| 2025-08-25 10:00 |
Board/Management Information
Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D., Ph.D., World-R…
|
English | 13.2 KB | ||
| 2025-08-21 22:05 |
Earnings Release
Oculis birtir uppgjör fyrir annan ársfjórðung 2025 og kynnir áfanga í rekstri f…
|
Icelandic | 20.6 KB | ||
| 2025-08-21 22:05 |
Earnings Release
Oculis Reports Q2 2025 Financial Results and Provides Company Update
|
English | 18.3 KB | ||
| 2025-08-12 10:00 |
Report Publication Announcement
Oculis to Participate in Upcoming H.C Wainwright 5th Annual Ophthalmology Virtu…
|
English | 4.2 KB | ||
| 2025-08-01 10:00 |
Capital/Financing Update
Oculis hækkar lánsheimild sína og fær aðgang að allt að 100 milljónum CHF
|
Icelandic | 8.1 KB | ||
| 2025-08-01 10:00 |
Capital/Financing Update
Oculis Upsized Loan Facility to Access up to CHF 100 million
|
English | 7.1 KB |
Automate Your Workflow. Get a real-time feed of all Oculis Holding AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Oculis Holding AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
